Cargando…

Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series

Introduction: Limited data are available on the course of Coronavirus disease 2019 (COVID-19) in people with Multiple Sclerosis (MS). More real-world data are needed to help the MS community to manage MS treatment properly. In particular, it is important to understand the impact of immunosuppressive...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Mercanti, Stefania F., Vercellino, Marco, Bosa, Chiara, Alteno, Anastasia, Schillaci, Valentina, Clerico, Marinella, Cavalla, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563620/ https://www.ncbi.nlm.nih.gov/pubmed/34744958 http://dx.doi.org/10.3389/fneur.2021.691616

Ejemplares similares

Impact of COVID-19 lockdown on progressive multiple sclerosis patients
por: Vercellino, Marco, et al.
Publicado: (2022)

SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study
por: Vercellino, Marco, et al.
Publicado: (2023)

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab
por: Abbadessa, Gianmarco, et al.
Publicado: (2021)

Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
por: Garcia-Cañibano, Beatriz, et al.
Publicado: (2021)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
por: Sempere, Angel P., et al.
Publicado: (2021)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
por: Hughes, Richard, et al.
Publicado: (2020)

Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue
por: Koska, Valeria, et al.
Publicado: (2021)

Onset of multiple sclerosis in a patient on dupilumab therapy for atopic dermatitis: A case report
por: Gelato, Federica, et al.
Publicado: (2022)

The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View
por: Maglione, Alessandro, et al.
Publicado: (2019)

Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question
por: De Mercanti, Stefania Federica, et al.
Publicado: (2020)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

COVID-19 in ocrelizumab-treated people with multiple sclerosis
por: Hughes, Richard, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology
por: Mancinelli, Chiara Rosa, et al.
Publicado: (2021)

Ocrelizumab: A Review in Multiple Sclerosis
por: Lamb, Yvette N.
Publicado: (2022)

Breast Carcinoma After Ocrelizumab Therapy in Multiple Sclerosis Patients: A Case Series and Literature Review
por: Kelsey, Andrew, et al.
Publicado: (2021)

Family Functioning and Multiple Sclerosis: Study Protocol of a Multicentric Italian Project
por: Di Tella, Marialaura, et al.
Publicado: (2021)

Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022)

Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe
por: Aun, Marcelo Vivolo, et al.
Publicado: (2022)

Aging in multiple sclerosis: from childhood to old age, etiopathogenesis, and unmet needs: a narrative review
por: Capasso, Nicola, et al.
Publicado: (2023)

CADASIL vs. Multiple Sclerosis: Is It Misdiagnosis or Concomitant? A Case Series
por: Khan, Ayesha, et al.
Publicado: (2020)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases
por: Nistri, Riccardo, et al.
Publicado: (2021)

Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
por: Chisari, Clara G., et al.
Publicado: (2023)

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
por: Suwanwongse, Kulachanya, et al.
Publicado: (2020)

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab
por: Pedotti, Rosetta, et al.
Publicado: (2021)

Ocrelizumab: a new milestone in multiple sclerosis therapy
por: Mulero, Patricia, et al.
Publicado: (2018)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis
por: Chey, Shin Yee, et al.
Publicado: (2022)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

Sex effects across the lifespan in women with multiple sclerosis
por: Krysko, Kristen M., et al.
Publicado: (2020)

Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies
por: Feng, Jenny J, et al.
Publicado: (2017)

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study
por: Weber, Martin S., et al.
Publicado: (2022)

Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series
por: Quintanilla-Bordás, Carlos, et al.
Publicado: (2022)

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up
por: Rolla, Simona, et al.
Publicado: (2022)

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
por: Seery, Nabil, et al.
Publicado: (2021)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
por: Frau, Jessica, et al.
Publicado: (2018)

Ocrelizumab Depletes CD20(+) T Cells in Multiple Sclerosis Patients
por: Gingele, Stefan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1f63g1pamrr62annbfndskqr8s